Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

The Tencent-backed social gaming platform developer had been reported to be targeting an $8bn valuation in its initial public offering.

Ride hailing service Dida Chuxing will reportedly target $500m in the offering, which would represent an exit for Nio Capital, BitAuto, JD.com and Ctrip,

Novo and Roche are in line for exits from hepatitis drug developer Aligos Therapeutics, which has raised some $230m since it was founded in 2018.

GV, Orient Life and Illumina Ventures are in line to exit cell therapy and vaccine developer SQZ Biotechnologies, which has filed for a $75m offering.

Recruit Strategic Partners has exited the identity management platform developer in a purchase by Ping Identity.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

GV is set to exit customer data management platform Segment in an all-share deal that more than doubles its valuation from 18 months ago.